ReviewDrug design, development and therapy2026
Tumor Microenvironment-Responsive Smart Hydrogel: Engineering Next-Generation in situ Tumor Vaccines for Synergistic Tumor Immunotherapy.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor vaccines represent a promising approach for tumor immunotherapy, yet their clinical translation is greatly impeded by cumbersome antigen screening, poor adaptation to tumor heterogeneity, inefficient antigen presentation, and insufficient immune activation. Tumor microenvironment (TME)-responsive smart hydrogels have emerged as advanced platforms for constructing next‑generation whole‑cell tumor vaccines, featuring tunable microstructures, spatiotemporally controlled cargo release, and excellent in situ TME adaptability. These hydrogel‑based vaccines directly employ intact tumor tissues as broad‑spectrum antigen reservoirs, avoiding complex antigen isolation and identification to effectively overcome tumor heterogeneity. Hydrogel‑based vaccines enable stimuli‑responsive sequential release of antigens, adjuvants, and bioactive factors, precisely modulating immune cascades to elicit robust systemic antitumor immunity against tumor growth, invasion, and metastasis. This review systematically summarizes the design principles, fabrication strategies, and immunomodulatory mechanisms of TME‑responsive hydrogel‑based whole‑cell vaccines, highlights their structure-efficacy relationships, and discusses key challenges in clinical translation. Furthermore, this review proposes future directions to guide the rational development of high‑performance immunotherapeutic formulation with strong clinical potential for personalized tumor treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.